Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches

Next Previous
Trial Profile

Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 16 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Cluster headache
  • Focus Therapeutic Use
  • Acronyms ATAC
  • Sponsors Zosano Pharma

Most Recent Events

  • 12 Jun 2022 According to 64th Annual Scientific Meeting of the American Headache Society, most clinical trial sites became active in 2020, which resulted in several sites being closed and made enrollment very difficult, and thus the trial was stopped early.
  • 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society
  • 12 Jun 2022 Status changed to discontinued , according to Results presented at the 64th Annual Scientific Meeting of the American Headache Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top